CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | organic aromatic compound |
|
Accession: | CHEBI:33659
|
browse the term
|
Synonyms: | related_synonym: | organic aromatic compounds |
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [alpha-naphthoflavone results in increased activity of AHR protein] |
CTD |
PMID:12970578 PMID:22521609 |
|
NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions decreases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein]; epigallocatechin gallate inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; HMOX1 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] epigallocatechin gallate results in decreased expression of CCL2 mRNA |
CTD |
PMID:20580034 PMID:22521609 PMID:23380242 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions decreases activity decreases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [beta-Naphthoflavone results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] epigallocatechin gallate results in decreased activity of CYP1A1 protein epigallocatechin gallate results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:12970578 PMID:22521609 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
GSTO1 |
glutathione S-transferase omega 1 |
multiple interactions increases expression |
EXP |
[epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of GSTO1 mRNA; NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of GSTO1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr14:115,206,434...115,216,624
Ensembl chr14:115,206,188...115,216,613
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
EXP |
HMOX1 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] |
CTD |
PMID:20580034 |
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of GSTO1 mRNA]; NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of NQO1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP |
epigallocatechin gallate results in increased expression of NQO1 mRNA [epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [epigallocatechin gallate results in increased expression of NQO1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Penicillins]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; HMOX1 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] |
CTD |
PMID:20580034 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; epigallocatechin gallate inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] epigallocatechin gallate results in decreased expression of VCAM1 mRNA |
CTD |
PMID:22521609 PMID:23380242 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
AMBP |
alpha-1-microglobulin/bikunin precursor |
decreases uptake |
EXP |
Colchicine results in decreased uptake of AMBP protein |
CTD |
PMID:9019736 |
|
NCBI chr 1:254,683,885...254,703,220
Ensembl chr 1:254,683,891...254,703,225
|
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
increases activity |
EXP |
o,p'-DDT results in increased activity of CYP19A1 protein |
CTD |
PMID:18195494 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
ESR2 |
estrogen receptor 2 |
decreases expression |
EXP |
o,p'-DDT results in decreased expression of ESR2 protein |
CTD |
PMID:18195494 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
|
G |
ANPEP |
alanyl aminopeptidase, membrane |
multiple interactions decreases activity |
EXP |
Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] |
CTD |
PMID:17109655 |
|
NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,087...55,373,881
|
|
G |
ENPEP |
glutamyl aminopeptidase |
multiple interactions |
EXP |
1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame] |
CTD |
PMID:8141778 |
|
NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
|
|
|
G |
LOC100739508 |
glutathione S-transferase P-like |
affects metabolic processing |
EXP |
GSTP1 protein affects the metabolism of Dinitrochlorobenzene |
CTD |
PMID:14573868 |
|
NCBI chr 2:5,005,498...5,009,247
|
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
EXP |
Estradiol results in increased phosphorylation of ACACA protein |
CTD |
PMID:15967841 |
|
NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,457...38,824,712
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases secretion |
EXP |
Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; bisphenol A promotes the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Estradiol results in increased expression of and results in increased secretion of ADIPOQ protein; halowax 1051 inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Hexachlorobenzene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol] |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
increases expression |
EXP |
Estradiol results in increased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
increases expression |
EXP |
Estradiol results in increased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
Estradiol results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17348974 |
|
|
|
G |
CD40 |
CD40 molecule |
affects expression |
EXP |
Estradiol affects the expression of CD40 protein |
CTD |
PMID:15964915 |
|
NCBI chr17:48,286,116...48,298,188
Ensembl chr17:48,286,029...48,298,528
|
|
G |
CD40LG |
CD40 ligand |
affects expression |
EXP |
Estradiol affects the expression of CD40LG protein |
CTD |
PMID:15964915 |
|
NCBI chr X:111,778,666...111,788,901
Ensembl chr X:111,778,493...111,789,709
|
|
G |
ESR1 |
estrogen receptor 1 |
decreases expression affects expression |
EXP |
Estradiol results in decreased expression of ESR1 protein; Estradiol results in decreased expression of ESR1 protein alternative form Estradiol affects the expression of ESR1 protein |
CTD |
PMID:15653758 PMID:16431846 PMID:16680078 PMID:17348974 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
ESR2 |
estrogen receptor 2 |
affects expression |
EXP |
Estradiol affects the expression of ESR2 protein |
CTD |
PMID:15653758 PMID:16680078 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
G |
F3 |
coagulation factor III, tissue factor |
affects expression |
EXP |
Estradiol affects the expression of F3 mRNA; Estradiol affects the expression of F3 protein |
CTD |
PMID:15964915 |
|
NCBI chr 4:122,827,018...122,837,673
Ensembl chr 4:122,826,644...122,837,666
|
|
G |
FGF7 |
fibroblast growth factor 7 |
increases expression |
EXP |
Estradiol results in increased expression of FGF7 mRNA |
CTD |
PMID:15271478 |
|
NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,882...122,277,750
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions increases chemical synthesis |
EXP |
4,4'-hexafluorisopropylidene diphenol inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol]; [FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol; [FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol; bisphenol S inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol]; deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; lead acetate inhibits the reaction [FSHB protein results in increased chemical synthesis of Estradiol] |
CTD |
PMID:17656051 PMID:29273543 PMID:34019995 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
HOXA10 |
homeobox A10 |
increases expression multiple interactions |
EXP |
Estradiol results in increased expression of HOXA10 mRNA Estradiol promotes the reaction [Progesterone results in increased expression of HOXA10 mRNA]; Fulvestrant inhibits the reaction [Estradiol results in increased expression of HOXA10 mRNA] |
CTD |
PMID:21705055 |
|
NCBI chr18:45,393,525...45,403,259
Ensembl chr18:45,393,885...45,403,257
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions increases abundance |
EXP |
[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol; deoxynivalenol affects the reaction [[FSHB protein co-treated with IGF1 protein] results in increased abundance of Estradiol]; deoxynivalenol affects the reaction [IGF1 protein results in increased abundance of Estradiol]; Zearalenone affects the reaction [IGF1 protein results in increased abundance of Estradiol] |
CTD |
PMID:17656051 |
|
NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033
|
|
G |
LEP |
leptin |
increases secretion increases expression |
EXP |
Estradiol results in increased secretion of LEP protein Estradiol results in increased expression of LEP mRNA |
CTD |
PMID:23153703 |
|
NCBI chr18:20,106,867...20,124,071
Ensembl chr18:20,106,868...20,123,323
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions increases secretion |
EXP |
Biological Products inhibits the reaction [LHB protein results in increased secretion of Estradiol]; Cod Liver Oil inhibits the reaction [LHB protein results in increased secretion of Estradiol]; Industrial Waste inhibits the reaction [LHB protein results in increased secretion of Estradiol] |
CTD |
PMID:26055946 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
affects secretion |
EXP |
Estradiol affects the secretion of MMP2 protein |
CTD |
PMID:15653758 |
|
NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,595...30,086,982
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions affects expression increases phosphorylation decreases expression |
EXP |
Estradiol results in increased phosphorylation of and results in increased activity of NOS3 protein; Fulvestrant inhibits the reaction [Estradiol results in increased phosphorylation of NOS3 protein] Estradiol affects the expression of NOS3 mRNA Estradiol results in decreased expression of NOS3 mRNA |
CTD |
PMID:15653758 PMID:15967841 PMID:16680078 PMID:17618301 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
PDGFB |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
Estradiol affects the secretion of [PDGFB protein binds to PDGFB protein] |
CTD |
PMID:15653758 |
|
Ensembl chr 5:8,986,462...9,007,435
|
|
G |
PGR |
progesterone receptor |
increases expression |
EXP |
Estradiol results in increased expression of PGR mRNA |
CTD |
PMID:16431846 |
|
NCBI chr 9:32,035,684...32,129,776
Ensembl chr 9:32,035,684...32,129,221
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
Estradiol results in increased phosphorylation of and results in increased activity of PRKAA1 protein |
CTD |
PMID:15967841 |
|
NCBI chr16:25,745,902...25,783,524
Ensembl chr16:25,745,324...25,783,707
|
|
G |
PRLR |
prolactin receptor |
increases expression |
EXP |
Estradiol results in increased expression of PRLR protein alternative form |
CTD |
PMID:18492821 |
|
NCBI chr16:20,637,568...20,655,881
Ensembl chr16:20,618,875...20,810,140
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
Estradiol results in increased expression of PTGS2 mRNA Fulvestrant inhibits the reaction [Estradiol results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21705055 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
Estradiol results in decreased expression of SPP1 protein |
CTD |
PMID:15713688 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
increases expression |
EXP |
Estradiol results in increased expression of TNFRSF11B protein |
CTD |
PMID:15713688 |
|
NCBI chr 4:19,850,212...19,879,132
Ensembl chr 4:19,850,350...19,879,125
|
|
|
G |
FGF7 |
fibroblast growth factor 7 |
affects expression |
EXP |
estradiol 3-benzoate affects the expression of FGF7 mRNA |
CTD |
PMID:15976484 |
|
NCBI chr 1:122,215,878...122,278,705
Ensembl chr 1:122,215,882...122,277,750
|
|
G |
FGFR2 |
fibroblast growth factor receptor 2 |
decreases expression multiple interactions |
EXP |
estradiol 3-benzoate results in decreased expression of FGFR2 mRNA alternative form [Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of FGFR2 mRNA alternative form |
CTD |
PMID:15976484 |
|
NCBI chr14:131,183,095...131,285,001
Ensembl chr14:131,181,713...131,289,425
|
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
decreases activity |
EXP |
2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of CYP11A1 protein |
CTD |
PMID:16151981 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
multiple interactions decreases activity |
EXP |
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Testosterone] affects the activity of CYP19A1 protein 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of CYP19A1 protein |
CTD |
PMID:16151981 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
HSD17B1 |
hydroxysteroid 17-beta dehydrogenase 1 |
multiple interactions decreases activity |
EXP |
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Androstenedione] results in increased activity of HSD17B1 protein 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased activity of HSD17B1 protein |
CTD |
PMID:16151981 |
|
NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548
|
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [ADIPOQ protein results in increased secretion of Testosterone]; 2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of ADIPOQ protein |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
increases expression |
EXP |
2,2',4,4'-tetrabromodiphenyl ether results in increased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
increases expression |
EXP |
2,2',4,4'-tetrabromodiphenyl ether results in increased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
COMT |
catechol-O-methyltransferase |
increases activity |
EXP |
2,2',4,4'-tetrabromodiphenyl ether results in increased activity of COMT protein |
CTD |
PMID:22750137 |
|
NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
increases expression multiple interactions |
EXP |
2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of CYP19A1 mRNA; 2,2',4,4'-tetrabromodiphenyl ether results in increased expression of CYP19A1 protein 2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of and results in increased activity of CYP19A1 protein; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]; Fadrozole inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of and results in increased activity of CYP19A1 protein] |
CTD |
PMID:23146758 PMID:28284726 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
ESR1 |
estrogen receptor 1 |
increases expression |
EXP |
2,2',4,4'-tetrabromodiphenyl ether metabolite results in increased expression of ESR1 mRNA; 2,2',4,4'-tetrabromodiphenyl ether metabolite results in increased expression of ESR1 protein |
CTD |
PMID:24956591 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
ESR2 |
estrogen receptor 2 |
increases expression decreases expression |
EXP |
2,2',4,4'-tetrabromodiphenyl ether metabolite results in increased expression of ESR2 mRNA; 2,2',4,4'-tetrabromodiphenyl ether metabolite results in increased expression of ESR2 protein 2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ESR2 mRNA; 2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ESR2 protein |
CTD |
PMID:24956591 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
G |
HSD17B1 |
hydroxysteroid 17-beta dehydrogenase 1 |
increases expression |
EXP |
2,2',4,4'-tetrabromodiphenyl ether results in increased expression of HSD17B1 protein |
CTD |
PMID:21871953 |
|
NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548
|
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
increases activity |
EXP |
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CYP19A1 protein |
CTD |
PMID:18195494 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
ESR2 |
estrogen receptor 2 |
decreases expression |
EXP |
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in decreased expression of ESR2 protein |
CTD |
PMID:18195494 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
TPO |
thyroid peroxidase |
decreases activity |
EXP |
2,3-dimethoxy-1,4-naphthoquinone results in decreased activity of TPO protein |
CTD |
PMID:11815678 |
|
NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208
|
|
|
G |
AMBP |
alpha-1-microglobulin/bikunin precursor |
decreases uptake |
EXP |
2,4-Dinitrophenol results in decreased uptake of AMBP protein |
CTD |
PMID:9019736 |
|
NCBI chr 1:254,683,885...254,703,220
Ensembl chr 1:254,683,891...254,703,225
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression |
EXP |
2,4-Dinitrophenol results in increased expression of NOS3 mRNA |
CTD |
PMID:11382920 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
increases expression |
EXP |
Butylated Hydroxytoluene results in increased expression of GCLC mRNA |
CTD |
PMID:9535746 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines] |
CTD |
PMID:21056966 |
|
NCBI chr 9:93,171,371...93,262,124
|
|
|
G |
ATP7B |
ATPase copper transporting beta |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [Copper binds to ATP7B protein] |
CTD |
PMID:21084060 |
|
NCBI chr11:15,892,549...15,942,070
Ensembl chr11:15,876,612...15,942,064
|
|
G |
CALCB |
calcitonin-related polypeptide beta |
increases abundance |
EXP |
CALCA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18463244 |
|
NCBI chr 2:44,043,135...44,048,651
|
|
G |
DUOX2 |
dual oxidase 2 |
increases expression |
EXP |
Cyclic AMP results in increased expression of DUOX2 mRNA |
CTD |
PMID:10601291 |
|
NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406
|
|
G |
GCG |
glucagon |
affects response to substance increases abundance |
EXP |
Cyclic AMP affects the susceptibility to GCG protein GCG protein results in increased abundance of Cyclic AMP |
CTD |
PMID:6253273 |
|
NCBI chr15:68,800,557...68,810,268
Ensembl chr15:68,800,560...68,810,242
|
|
G |
GNRH1 |
gonadotropin releasing hormone 1 |
multiple interactions increases abundance |
EXP |
[Cobalt binds to GNRH1 protein] which results in increased abundance of Cyclic AMP GNRH1 protein results in increased abundance of Cyclic AMP |
CTD |
PMID:15833593 |
|
NCBI chr14:9,442,971...9,447,521
Ensembl chr14:9,442,971...9,453,035
|
|
|
G |
PDE5A |
phosphodiesterase 5A |
increases degradation |
EXP |
PDE5 protein results in increased degradation of Cyclic GMP |
CTD |
PMID:18669600 |
|
NCBI chr 8:104,270,858...104,420,955
Ensembl chr 8:104,270,881...104,420,953
|
|
G |
PDE6C |
phosphodiesterase 6C |
increases degradation |
EXP |
PDE6C protein results in increased degradation of Cyclic GMP |
CTD |
PMID:18669600 |
|
NCBI chr14:105,010,974...105,122,628
Ensembl chr14:105,050,691...105,122,421
|
|
G |
PRKG1 |
protein kinase cGMP-dependent 1 |
increases activity |
EXP |
Cyclic GMP results in increased activity of PRKG1 protein |
CTD |
PMID:18037907 |
|
NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,558,533...98,793,010
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
increases expression multiple interactions increases activity |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of AHR protein epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased activity of AHR protein] |
CTD |
PMID:16552988 PMID:22521609 |
|
NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
|
|
G |
CAV1 |
caveolin 1 |
multiple interactions |
EXP |
CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; CAV1 mutant form promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA] |
CTD |
PMID:19265715 PMID:20406653 PMID:24709675 |
|
NCBI chr18:29,648,120...29,682,451
Ensembl chr18:29,649,992...29,682,465
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
increases expression multiple interactions |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA] |
CTD |
PMID:19265715 PMID:22521609 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CTSB |
cathepsin B |
decreases expression |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of CTSB mRNA |
CTD |
PMID:16291828 |
|
NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,033,877
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
decreases activity |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in decreased activity of CYP11A1 protein |
CTD |
PMID:16151981 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
increases activity multiple interactions |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP19A1 protein [3,4,5,3',4'-pentachlorobiphenyl co-treated with Testosterone] results in increased activity of CYP19A1 protein |
CTD |
PMID:16151981 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases expression |
EXP |
epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein] 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein |
CTD |
PMID:16291828 PMID:19608276 PMID:22521609 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
GSTO1 |
glutathione S-transferase omega 1 |
multiple interactions |
EXP |
[epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of GSTO1 mRNA |
CTD |
PMID:22521609 |
|
NCBI chr14:115,206,434...115,216,624
Ensembl chr14:115,206,188...115,216,613
|
|
G |
HSD17B1 |
hydroxysteroid 17-beta dehydrogenase 1 |
decreases activity |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in decreased activity of HSD17B1 protein |
CTD |
PMID:16151981 |
|
NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:20406653 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:20406653 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CCL2 mRNA]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 mRNA]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA] |
CTD |
PMID:22521609 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA [epigallocatechin gallate co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased expression of NQO1 mRNA; CAV1 mutant form promotes the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NQO1 mRNA] |
CTD |
PMID:22521609 PMID:24709675 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
G |
SLC5A5 |
solute carrier family 5 member 5 |
decreases expression |
EXP |
3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of SLC5A5 mRNA |
CTD |
PMID:16291828 |
|
NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein]; NFE2L2 protein affects the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA] 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 mRNA; 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of VCAM1 protein |
CTD |
PMID:20406653 PMID:22521609 PMID:24709675 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein; [alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein] |
CTD |
PMID:12970578 |
|
NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
|
|
G |
CAV1 |
caveolin 1 |
multiple interactions |
EXP |
3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein; CAV1 mutant form inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein] |
CTD |
PMID:19608276 PMID:20406653 |
|
NCBI chr18:29,648,120...29,682,451
Ensembl chr18:29,649,992...29,682,465
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
increases secretion increases expression multiple interactions |
EXP |
3,4,3',4'-tetrachlorobiphenyl results in increased secretion of CCL2 protein 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Eicosapentaenoic Acid] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; [2,2'-azobis(2-amidinopropane) results in increased oxidation of Eicosapentaenoic Acid] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein]; Acetylcysteine inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; sodium borohydride inhibits the reaction [[2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]]; sulforaphane inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; Tretinoin promotes the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 protein] |
CTD |
PMID:19265715 PMID:21130106 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases activity increases expression multiple interactions |
EXP |
3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA; 3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein] |
CTD |
PMID:12970578 PMID:19608276 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20406653 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20406653 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
increases activity multiple interactions |
EXP |
3,4,3',4'-tetrachlorobiphenyl results in increased activity of RELA protein [2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of RELA protein] |
CTD |
PMID:21130106 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
SELE |
selectin E |
increases expression multiple interactions |
EXP |
3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA] |
CTD |
PMID:19608276 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
G |
SELP |
selectin P |
multiple interactions increases expression |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELP mRNA] |
CTD |
PMID:19608276 |
|
NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,399,955
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA]; CAV1 mutant form inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA] 3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA; 3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 protein |
CTD |
PMID:19608276 PMID:20406653 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
AGO2 |
argonaute RISC catalytic component 2 |
decreases expression multiple interactions |
EXP |
tetrabromobisphenol A results in decreased expression of AGO2 protein [tetrabromobisphenol A co-treated with 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline] results in decreased expression of AGO2 protein |
CTD |
PMID:31266599 |
|
NCBI chr 4:2,966,794...3,012,388
Ensembl chr 4:2,919,511...3,015,334
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
tetrabromobisphenol A results in decreased expression of AKT1 mRNA; tetrabromobisphenol A results in decreased expression of AKT1 protein |
CTD |
PMID:35665993 |
|
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases activity |
EXP |
tetrabromobisphenol A results in decreased activity of ATP2A2 protein |
CTD |
PMID:17784851 |
|
NCBI chr14:31,674,659...31,744,981
Ensembl chr14:31,674,757...31,744,969
|
|
G |
ATP2A3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
decreases activity |
EXP |
tetrabromobisphenol A results in decreased activity of ATP2A3 protein |
CTD |
PMID:17784851 |
|
NCBI chr12:49,980,488...50,014,006
Ensembl chr12:49,980,497...50,025,171
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
tetrabromobisphenol A results in increased expression of BAX mRNA; tetrabromobisphenol A results in increased expression of BAX protein Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX protein] |
CTD |
PMID:35665993 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
tetrabromobisphenol A results in decreased expression of BCL2 mRNA; tetrabromobisphenol A results in decreased expression of BCL2 protein |
CTD |
PMID:35665993 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
increases expression multiple interactions |
EXP |
tetrabromobisphenol A results in increased expression of CASP3 mRNA; tetrabromobisphenol A results in increased expression of CASP3 protein Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 protein] |
CTD |
PMID:35665993 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 protein] tetrabromobisphenol A results in decreased expression of CASP8 mRNA; tetrabromobisphenol A results in decreased expression of CASP8 protein |
CTD |
PMID:35665993 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 protein] tetrabromobisphenol A results in increased expression of CASP9 mRNA; tetrabromobisphenol A results in increased expression of CASP9 protein |
CTD |
PMID:35665993 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
COX7A2L |
cytochrome c oxidase subunit 7A2 like |
increases expression multiple interactions |
EXP |
tetrabromobisphenol A results in increased expression of COX7A2L mRNA Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of COX7A2L mRNA] |
CTD |
PMID:35665993 |
|
NCBI chr 3:97,951,115...97,983,309
Ensembl chr 3:97,951,114...97,983,309
|
|
G |
DICER1 |
dicer 1, ribonuclease III |
decreases expression multiple interactions |
EXP |
tetrabromobisphenol A results in decreased expression of DICER1 mRNA; tetrabromobisphenol A results in decreased expression of DICER1 protein [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with tetrabromobisphenol A] results in decreased expression of DICER1 mRNA; [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with tetrabromobisphenol A] results in decreased expression of DICER1 protein |
CTD |
PMID:31266599 |
|
NCBI chr 7:116,361,630...116,436,471
Ensembl chr 7:116,365,802...116,411,224
|
|
G |
DROSHA |
drosha ribonuclease III |
increases expression |
EXP |
tetrabromobisphenol A results in increased expression of DROSHA mRNA |
CTD |
PMID:31266599 |
|
NCBI chr16:17,727,695...17,847,954
Ensembl chr16:17,565,137...17,848,162
|
|
G |
GPER1 |
G protein-coupled estrogen receptor 1 |
decreases expression multiple interactions |
EXP |
tetrabromobisphenol A results in decreased expression of GPER1 protein [tetrabromobisphenol A co-treated with 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline] results in decreased expression of GPER1 protein |
CTD |
PMID:31266599 |
|
NCBI chr 3:711,427...715,982
Ensembl chr 3:712,160...715,980
|
|
G |
LOC100623720 |
collagen alpha-1(VI) chain |
increases expression multiple interactions |
EXP |
tetrabromobisphenol A results in increased expression of COL6A1 protein 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [tetrabromobisphenol A results in increased expression of COL6A1 protein]; tetrabromobisphenol A inhibits the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of COL6A1 protein] |
CTD |
PMID:31266599 |
|
NCBI chr13:208,295,245...208,321,789
Ensembl chr13:208,295,451...208,313,127
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases expression |
EXP |
[4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with tetrabromobisphenol A] results in increased expression of MAP1LC3B protein tetrabromobisphenol A results in increased expression of MAP1LC3B protein |
CTD |
PMID:31266599 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
MLKL |
mixed lineage kinase domain like pseudokinase |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL protein] tetrabromobisphenol A results in increased expression of MLKL mRNA; tetrabromobisphenol A results in increased expression of MLKL protein |
CTD |
PMID:35665993 |
|
NCBI chr 6:12,923,846...12,951,176
Ensembl chr 6:12,924,894...12,951,173
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
decreases expression |
EXP |
tetrabromobisphenol A results in decreased expression of PIK3CG mRNA; tetrabromobisphenol A results in decreased expression of PIK3CG protein |
CTD |
PMID:35665993 |
|
NCBI chr 9:106,698,200...106,748,217
Ensembl chr 9:106,698,207...106,745,099
|
|
G |
PLIN1 |
perilipin 1 |
multiple interactions increases expression |
EXP |
[tetrabromobisphenol A co-treated with 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline] results in increased expression of PLIN1 protein tetrabromobisphenol A results in increased expression of PLIN1 protein |
CTD |
PMID:31266599 |
|
NCBI chr 7:55,237,517...55,250,797
Ensembl chr 7:55,236,348...55,250,797
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN protein] tetrabromobisphenol A results in increased expression of PTEN mRNA; tetrabromobisphenol A results in increased expression of PTEN protein |
CTD |
PMID:35665993 |
|
NCBI chr14:99,929,590...100,021,619
|
|
G |
RIPK1 |
receptor interacting serine/threonine kinase 1 |
increases expression multiple interactions |
EXP |
tetrabromobisphenol A results in increased expression of RIPK1 mRNA; tetrabromobisphenol A results in increased expression of RIPK1 protein Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 protein] |
CTD |
PMID:35665993 |
|
NCBI chr 7:1,841,143...1,880,705
Ensembl chr 7:1,841,239...1,880,699
|
|
G |
RIPK3 |
receptor interacting serine/threonine kinase 3 |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 protein] tetrabromobisphenol A results in increased expression of RIPK3 mRNA; tetrabromobisphenol A results in increased expression of RIPK3 protein |
CTD |
PMID:35665993 |
|
NCBI chr 7:74,951,145...74,955,255
Ensembl chr 7:74,951,145...74,955,251
|
|
G |
XPO5 |
exportin 5 |
multiple interactions decreases expression |
EXP |
[4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with tetrabromobisphenol A] results in decreased expression of XPO5 mRNA; [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with tetrabromobisphenol A] results in decreased expression of XPO5 protein tetrabromobisphenol A results in decreased expression of XPO5 protein |
CTD |
PMID:31266599 |
|
NCBI chr 7:38,530,704...38,569,558
Ensembl chr 7:38,531,919...38,569,582
|
|
|
G |
ALOX5AP |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
EXP |
MK-886 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein] |
CTD |
PMID:21658425 |
|
NCBI chr11:7,371,328...7,438,111
Ensembl chr11:7,411,644...7,438,108
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
MK-886 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA] |
CTD |
PMID:15089098 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
EXP |
bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA] |
CTD |
PMID:15089098 |
|
NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BAX mRNA] |
CTD |
PMID:28803810 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BECN1 protein] |
CTD |
PMID:28803810 PMID:34811946 |
|
NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein] |
CTD |
PMID:28803810 PMID:30287338 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP8 protein] |
CTD |
PMID:28803810 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein] |
CTD |
PMID:34811946 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of CYCS mRNA] |
CTD |
PMID:28803810 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
DCTN4 |
dynactin subunit 4 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr 2:151,681,001...151,713,923
Ensembl chr 2:151,681,003...151,783,746
|
|
G |
FGD4 |
FYVE, RhoGEF and PH domain containing 4 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]] |
CTD |
PMID:34811946 |
|
NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028
|
|
G |
FIS1 |
fission, mitochondrial 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr 3:8,938,250...8,942,102
Ensembl chr 3:8,937,453...8,946,955
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
decreases expression |
EXP |
3-methyladenine results in decreased expression of LAMP2 protein |
CTD |
PMID:36754226 |
|
NCBI chr X:98,586,718...98,623,939
Ensembl chr X:98,556,710...98,623,940
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions decreases lipidation |
EXP |
3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; Benzo(a)pyrene promotes the reaction [3-methyladenine results in decreased lipidation of MAP1LC3B protein] |
CTD |
PMID:34811946 PMID:36754226 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr14:137,266,622...137,296,312
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
|
|
G |
OPA1 |
OPA1 mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] |
CTD |
PMID:30287338 PMID:34811946 |
|
NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:28803810 PMID:34811946 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TOMM20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr14:56,113,087...56,127,686
Ensembl chr14:56,113,192...56,127,677
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
|
G |
SLC4A2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid promotes the reaction [SLC4A2 protein binds to SLC4A2 protein] |
CTD |
PMID:10387099 |
|
NCBI chr18:6,149,459...6,166,622
Ensembl chr18:6,149,459...6,165,212
|
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
affects expression decreases expression |
EXP |
bisphenol S affects the expression of CYP19A1 protein bisphenol S results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28352085 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
ESR1 |
estrogen receptor 1 |
decreases expression increases expression |
EXP |
bisphenol S results in decreased expression of ESR1 mRNA bisphenol S results in increased expression of ESR1 protein |
CTD |
PMID:28352085 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
ESR2 |
estrogen receptor 2 |
increases expression decreases expression |
EXP |
bisphenol S results in increased expression of ESR2 protein bisphenol S results in decreased expression of ESR2 mRNA |
CTD |
PMID:28352085 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
bisphenol S inhibits the reaction [[FSHB protein co-treated with Androstenedione] results in increased chemical synthesis of and results in increased secretion of Estradiol]; bisphenol S inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone] |
CTD |
PMID:34019995 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
|
G |
CD44 |
CD44 molecule |
decreases expression |
EXP |
Hymecromone results in decreased expression of CD44 mRNA |
CTD |
PMID:23139787 |
|
NCBI chr 2:25,788,699...25,884,209
Ensembl chr 2:25,788,703...25,884,153
|
|
G |
FBN1 |
fibrillin 1 |
decreases expression |
EXP |
Hymecromone results in decreased expression of FBN1 mRNA |
CTD |
PMID:23139787 |
|
NCBI chr 1:123,102,011...123,359,649
Ensembl chr 1:123,102,009...123,359,649
|
|
G |
FN1 |
fibronectin 1 |
decreases expression |
EXP |
Hymecromone results in decreased expression of FN1 mRNA; Hymecromone results in decreased expression of FN1 protein |
CTD |
PMID:23139787 |
|
NCBI chr15:117,658,158...117,737,145
Ensembl chr15:117,658,099...117,731,014
|
|
G |
TNC |
tenascin C |
decreases expression |
EXP |
Hymecromone results in decreased expression of TNC mRNA |
CTD |
PMID:23139787 |
|
NCBI chr 1:255,533,235...255,630,381
Ensembl chr 1:255,533,238...255,630,376
|
|
G |
VCAN |
versican |
decreases expression |
EXP |
Hymecromone results in decreased expression of VCAN mRNA; Hymecromone results in decreased expression of VCAN protein |
CTD |
PMID:23139787 |
|
NCBI chr 2:91,682,177...91,811,674
Ensembl chr 2:91,384,391...91,811,208
|
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
2-aminoacetophenone inhibits the reaction [[CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol]; [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol; Skatole inhibits the reaction [[CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol] |
CTD |
PMID:30599194 |
|
NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817
|
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions increases hydroxylation |
EXP |
2-aminoacetophenone inhibits the reaction [[CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol]; 2-aminoacetophenone inhibits the reaction [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol]; [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol; Skatole inhibits the reaction [[CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol]; Skatole inhibits the reaction [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] |
CTD |
PMID:30599194 |
|
NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
4-nonylphenol affects the phosphorylation of AKT1 protein |
CTD |
PMID:38246476 |
|
|
|
G |
PDPK1 |
3-phosphoinositide dependent protein kinase 1 |
increases phosphorylation |
EXP |
4-nonylphenol results in increased phosphorylation of PDPK1 protein |
CTD |
PMID:38246476 |
|
NCBI chr 3:39,429,928...39,512,623
Ensembl chr 3:39,432,058...39,512,601
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
EXP |
4-nonylphenol results in increased expression of PIK3R1 protein |
CTD |
PMID:38246476 |
|
NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,511,521...46,523,609
|
|
G |
PTEN |
phosphatase and tensin homolog |
increases expression |
EXP |
4-nonylphenol results in increased expression of PTEN protein |
CTD |
PMID:38246476 |
|
NCBI chr14:99,929,590...100,021,619
|
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein] |
CTD |
PMID:29080797 PMID:30923867 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein] |
CTD |
PMID:30923867 |
|
NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
|
|
G |
JAK2 |
Janus kinase 2 |
multiple interactions decreases phosphorylation |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein] Decitabine results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:30923867 |
|
NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,689...217,002,148
|
|
G |
NEIL1 |
nei like DNA glycosylase 1 |
multiple interactions increases expression |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA] Decitabine results in increased expression of NEIL1 mRNA |
CTD |
PMID:30923867 |
|
NCBI chr 7:58,261,761...58,269,001
Ensembl chr 7:58,261,769...58,268,522
|
|
G |
NEIL3 |
nei like DNA glycosylase 3 |
multiple interactions increases expression |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA] Decitabine results in increased expression of NEIL3 mRNA |
CTD |
PMID:30923867 |
|
NCBI chr15:39,416,073...39,632,313
Ensembl chr15:39,581,856...39,632,308
|
|
G |
OGG1 |
8-oxoguanine DNA glycosylase |
increases expression multiple interactions |
EXP |
Decitabine results in increased expression of OGG1 mRNA Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA] |
CTD |
PMID:30923867 |
|
NCBI chr13:66,038,669...66,045,478
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein] |
CTD |
PMID:30923867 |
|
NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,009
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30923867 |
|
NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992
|
|
|
G |
DAO |
D-amino acid oxidase |
decreases activity |
EXP |
5-methylpyrazole-3-carboxylic acid results in decreased activity of DAO protein |
CTD |
PMID:20952482 |
|
NCBI chr14:41,931,549...41,950,628
Ensembl chr14:41,931,541...41,950,633
|
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases expression |
EXP |
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP1A2 mRNA |
CTD |
PMID:24176340 |
|
NCBI chr 7:58,779,529...58,786,155
Ensembl chr 7:58,779,475...58,786,100
|
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
SOD1 protein affects the susceptibility to [Ditiocarb co-treated with 6-anilino-5,8-quinolinedione] |
CTD |
PMID:11861319 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein |
CTD |
PMID:11042205 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Aspirin inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein] |
CTD |
PMID:20665602 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
multiple interactions |
EXP |
Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:10706128 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
PPOX |
protoporphyrinogen oxidase |
decreases activity |
EXP |
acifluorfen results in decreased activity of PPOX protein |
CTD |
PMID:7697001 |
|
NCBI chr 4:89,277,984...89,288,946
Ensembl chr 4:89,284,500...89,288,902
|
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine results in decreased phosphorylation of MYL9 protein 8-phenyltheophylline inhibits the reaction [Adenosine results in decreased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
|
G |
CSNK1A1 |
casein kinase 1 alpha 1 |
decreases activity affects activity |
EXP |
Ageladine A analog results in decreased activity of CSNK1A1 protein Ageladine A affects the activity of CSNK1A1 protein |
CTD |
PMID:21413800 |
|
NCBI chr 2:150,612,845...150,662,431
Ensembl chr 2:150,612,077...150,662,284
|
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to alachlor |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
mangostin inhibits the reaction [Cisplatin results in increased expression of TP53] |
CTD |
PMID:20603111 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions increases activity |
EXP |
[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein; epigallocatechin gallate inhibits the reaction [[alpha-naphthoflavone co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [alpha-naphthoflavone results in increased activity of AHR protein] |
CTD |
PMID:12970578 |
|
NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
EXP |
alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA] |
CTD |
PMID:19265715 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases expression decreases activity |
EXP |
alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA] alpha-naphthoflavone results in increased expression of CYP1A1 mRNA alpha-naphthoflavone results in decreased activity of CYP1A1 protein |
CTD |
PMID:12970578 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
decreases expression |
EXP |
alternariol results in decreased expression of CYP11A1 protein |
CTD |
PMID:19429235 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
|
G |
EDN1 |
endothelin 1 |
decreases expression |
EXP |
ambrisentan results in decreased expression of EDN1 mRNA; ambrisentan results in decreased expression of EDN1 protein |
CTD |
PMID:16364719 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
EDNRA |
endothelin receptor type A |
decreases expression |
EXP |
ambrisentan results in decreased expression of EDNRA mRNA |
CTD |
PMID:16364719 |
|
NCBI chr 8:81,210,750...81,279,053
Ensembl chr 8:81,209,327...81,276,853
|
|
G |
IL6 |
interleukin 6 |
decreases expression |
EXP |
ambrisentan results in decreased expression of IL6 mRNA |
CTD |
PMID:16364719 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
decreases expression |
EXP |
ambrisentan results in decreased expression of IL1B mRNA |
CTD |
PMID:16364719 |
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
ambrisentan results in decreased expression of NOS3 mRNA |
CTD |
PMID:16364719 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
ambrisentan results in decreased expression of TNF mRNA |
CTD |
PMID:16364719 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
increases activity |
EXP |
Amiloride results in increased activity of CFTR protein |
CTD |
PMID:15246976 |
|
NCBI chr18:28,627,717...28,818,209
Ensembl chr18:28,627,728...28,817,950
|
|
G |
PLAU |
plasminogen activator, urokinase |
multiple interactions |
EXP |
Amiloride inhibits the reaction [[Asbestos, Crocidolite results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [[Asbestos, Serpentine results in increased activity of PLAU protein] which results in increased cleavage of PLG protein] |
CTD |
PMID:9853007 |
|
NCBI chr14:76,629,313...76,635,173
Ensembl chr14:76,629,299...76,635,172
|
|
G |
PLG |
plasminogen |
multiple interactions |
EXP |
Amiloride inhibits the reaction [[Asbestos, Crocidolite results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [[Asbestos, Serpentine results in increased activity of PLAU protein] which results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [Asbestos, Crocidolite results in increased cleavage of PLG protein]; Amiloride inhibits the reaction [Asbestos, Serpentine results in increased cleavage of PLG protein] |
CTD |
PMID:9853007 |
|
NCBI chr 1:7,062,399...7,109,521
Ensembl chr 1:7,061,192...7,110,555
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
multiple interactions |
EXP |
Amiloride promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA] |
CTD |
PMID:12081571 |
|
NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867
|
|
|
G |
GHRL |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
Aminoglutethimide promotes the reaction [GHRL protein results in decreased secretion of Progesterone] |
CTD |
PMID:22341706 |
|
NCBI chr13:66,442,106...66,453,576
Ensembl chr13:66,445,992...66,452,917
|
|
|
G |
AMBP |
alpha-1-microglobulin/bikunin precursor |
decreases uptake |
EXP |
Antimycin A results in decreased uptake of AMBP protein |
CTD |
PMID:9019736 |
|
NCBI chr 1:254,683,885...254,703,220
Ensembl chr 1:254,683,891...254,703,225
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein; Quercetin inhibits the reaction [[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein; Quercetin promotes the reaction [[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
|
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA] |
CTD |
PMID:26180592 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:26180592 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:26180592 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
ALOX5AP |
arachidonate 5-lipoxygenase activating protein |
increases expression multiple interactions |
EXP |
aristolochic acid I results in increased expression of ALOX5AP protein MK-886 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein]; U 0126 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein] |
CTD |
PMID:21658425 |
|
NCBI chr11:7,371,328...7,438,111
Ensembl chr11:7,411,644...7,438,108
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein; MK-886 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
LTC4S |
leukotriene C4 synthase |
decreases expression |
EXP |
aristolochic acid I results in decreased expression of LTC4S protein |
CTD |
PMID:21658425 |
|
NCBI chr 2:78,799,446...78,802,281
Ensembl chr 2:78,799,449...78,802,285
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:21658425 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MGST3 |
microsomal glutathione S-transferase 3 |
increases expression multiple interactions |
EXP |
aristolochic acid I results in increased expression of MGST3 protein U 0126 inhibits the reaction [aristolochic acid I results in increased expression of MGST3 protein] |
CTD |
PMID:21658425 |
|
NCBI chr 4:85,069,603...85,095,022
Ensembl chr 4:85,069,607...85,094,981
|
|
|
G |
FABP4 |
fatty acid binding protein 4 |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of FABP4 mRNA |
CTD |
PMID:15583048 |
|
NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896
|
|
G |
GPD1 |
glycerol-3-phosphate dehydrogenase 1 |
decreases activity |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased activity of GPD1 protein |
CTD |
PMID:15583048 |
|
NCBI chr 5:16,008,179...16,021,676
Ensembl chr 5:16,007,448...16,017,825
|
|
G |
NR2F1 |
nuclear receptor subfamily 2 group F member 1 |
increases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in increased expression of NR2F1 mRNA |
CTD |
PMID:15583048 |
|
NCBI chr 2:100,447,661...100,457,510
Ensembl chr 2:100,447,705...100,457,506
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of PPARG mRNA |
CTD |
PMID:15583048 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
RXRA |
retinoid X receptor alpha |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of RXRA mRNA |
CTD |
PMID:15583048 |
|
NCBI chr 1:273,698,842...273,797,622
Ensembl chr 1:273,705,505...273,797,620
|
|
G |
SREBP-1 |
sterol regulatory element binding protein 1 |
decreases expression |
EXP |
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid results in decreased expression of SREBP-1 mRNA |
CTD |
PMID:15583048 |
|
|
|
|
G |
ENPEP |
glutamyl aminopeptidase |
multiple interactions increases hydrolysis |
EXP |
1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame] |
CTD |
PMID:8141778 |
|
NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
|
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of BCL2 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein] |
CTD |
PMID:17997382 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions |
EXP |
Adenosine Triphosphate results in increased activity of CASP8 protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein] |
CTD |
PMID:17997382 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization multiple interactions |
EXP |
Adenosine Triphosphate affects the localization of CYCS protein [Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein] |
CTD |
PMID:16489745 PMID:17997382 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation multiple interactions |
EXP |
Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
EXP |
Adenosine Triphosphate results in increased expression of TNF protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein] |
CTD |
PMID:17997382 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
SLC9A1 |
solute carrier family 9 member A1 |
decreases activity |
EXP |
benzamide analog results in decreased activity of SLC9A1 protein |
CTD |
PMID:17724433 |
|
NCBI chr 6:84,373,921...84,426,447
Ensembl chr 6:84,372,649...84,426,997
|
|
|
G |
MOCOS |
molybdenum cofactor sulfurase |
affects reduction |
EXP |
MOCOS protein affects the reduction of benzamidoxime |
CTD |
PMID:16973608 |
|
NCBI chr 6:119,945,076...120,018,332
Ensembl chr 6:119,945,052...120,018,097
|
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]; Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Benzo(a)pyrene results in decreased expression of and results in decreased secretion of ADIPOQ protein |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of ATF4 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions increases expression |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of ATF6 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Benzo(a)pyrene results in increased expression of BAX protein |
CTD |
PMID:36754226 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of BCL2 protein |
CTD |
PMID:36754226 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression multiple interactions |
EXP |
Benzo(a)pyrene results in decreased expression of BCL2L1 protein 4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2L1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CCNB1 |
cyclin B1 |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of CCNB1 protein |
CTD |
PMID:36754226 |
|
NCBI chr16:47,338,239...47,348,385
Ensembl chr16:47,338,110...47,348,377
|
|
G |
CLDN1 |
claudin 1 |
decreases expression multiple interactions |
EXP |
Benzo(a)pyrene results in decreased expression of CLDN1 protein 4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of CLDN1 protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of CLDN1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CLDN3 |
claudin 3 |
decreases expression multiple interactions |
EXP |
Benzo(a)pyrene results in decreased expression of CLDN3 protein 4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of CLDN3 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,073...11,020,102
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
multiple interactions |
EXP |
Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein] |
CTD |
PMID:28284726 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression multiple interactions |
EXP |
Benzo(a)pyrene results in increased expression of CYP1A1 protein 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein |
CTD |
PMID:11042205 PMID:18636242 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression multiple interactions |
EXP |
Benzo(a)pyrene results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of DDIT3 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
Benzo(a)pyrene results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:36754226 |
|
NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
increases phosphorylation multiple interactions |
EXP |
Benzo(a)pyrene results in increased phosphorylation of ERN1 protein 4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284
|
|
G |
H2AX |
H2A.X variant histone |
increases expression |
EXP |
Benzo(a)pyrene results in increased expression of H2AX protein |
CTD |
PMID:36754226 |
|
NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA5 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
multiple interactions decreases expression |
EXP |
bafilomycin A1 inhibits the reaction [Benzo(a)pyrene results in decreased expression of LAMP2 protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of LAMP2 protein] |
CTD |
PMID:36754226 |
|
NCBI chr X:98,586,718...98,623,939
Ensembl chr X:98,556,710...98,623,940
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
decreases lipidation multiple interactions |
EXP |
Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein bafilomycin A1 inhibits the reaction [Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein]; Benzo(a)pyrene promotes the reaction [3-methyladenine results in decreased lipidation of MAP1LC3B protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein] |
CTD |
PMID:36754226 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of NFE2L2 protein |
CTD |
PMID:36754226 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
OCLN |
occludin |
decreases expression multiple interactions |
EXP |
Benzo(a)pyrene results in decreased expression of OCLN protein 4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of OCLN protein] |
CTD |
PMID:36754226 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
PCNA |
proliferating cell nuclear antigen |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of PCNA protein |
CTD |
PMID:36754226 |
|
NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744
|
|
G |
TJP1 |
tight junction protein 1 |
decreases expression multiple interactions |
EXP |
Benzo(a)pyrene results in decreased expression of TJP1 protein 4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of TJP1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TJP2 |
tight junction protein 2 |
decreases expression |
EXP |
Benzo(a)pyrene results in decreased expression of TJP2 protein |
CTD |
PMID:36754226 |
|
NCBI chr 1:222,474,518...222,612,989
Ensembl chr 1:222,474,639...222,612,983
|
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression increases activity multiple interactions |
EXP |
beta-Naphthoflavone results in increased expression of CYP1A1 mRNA; beta-Naphthoflavone results in increased expression of CYP1A1 protein beta-Naphthoflavone results in increased activity of CYP1A1 protein epigallocatechin gallate inhibits the reaction [beta-Naphthoflavone results in increased activity of CYP1A1 protein]; epigallocatechin gallate inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:12970578 PMID:19464568 PMID:19786062 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases expression |
EXP |
beta-Naphthoflavone results in increased expression of CYP1A2 mRNA |
CTD |
PMID:19464568 PMID:24176340 |
|
NCBI chr 7:58,779,529...58,786,155
Ensembl chr 7:58,779,475...58,786,100
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
increases expression |
EXP |
beta-Naphthoflavone results in increased expression of CYP1B1 mRNA |
CTD |
PMID:19464568 PMID:19786062 |
|
NCBI chr 3:102,195,743...102,205,687
Ensembl chr 3:102,195,741...102,205,683
|
|
|
G |
APOA1 |
apolipoprotein A1 |
increases expression increases secretion |
EXP |
Bezafibrate results in increased expression of APOA1 mRNA Bezafibrate results in increased secretion of APOA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [Cisplatin affects the localization of BAX protein] |
CTD |
PMID:16316343 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression |
EXP |
Bezafibrate results in increased expression of BCL2 |
CTD |
PMID:16316343 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:16316343 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [Cisplatin affects the localization of CYCS protein] |
CTD |
PMID:16316343 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
LIPG |
lipase G, endothelial type |
decreases expression |
EXP |
Bezafibrate results in decreased expression of LIPG mRNA; Bezafibrate results in decreased expression of LIPG protein |
CTD |
PMID:15953354 |
|
NCBI chr 1:99,081,940...99,110,671
Ensembl chr 1:99,081,938...99,110,874
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Bezafibrate inhibits the reaction [[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified]; Bezafibrate inhibits the reaction [Cisplatin results in decreased activity of PPARA protein] |
CTD |
PMID:16316343 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
affects localization increases expression |
EXP |
Bezafibrate affects the localization of SCARB1 protein Bezafibrate results in increased expression of SCARB1 mRNA |
CTD |
PMID:16530456 |
|
NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,568
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Bilirubin inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of CASP3 protein] |
CTD |
PMID:16371440 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
|
G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 |
increases expression |
EXP |
bisphenol A results in increased expression of ADCYAP1 protein |
CTD |
PMID:29569701 |
|
NCBI chr 6:105,414,628...105,422,294
Ensembl chr 6:105,414,631...105,422,294
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
bisphenol A inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]; bisphenol A inhibits the reaction [ADIPOQ protein results in increased secretion of Testosterone]; bisphenol A promotes the reaction [ADIPOQ protein results in increased secretion of Estradiol]; bisphenol A results in increased expression of and results in increased secretion of ADIPOQ protein |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
increases expression |
EXP |
bisphenol A results in increased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
increases expression |
EXP |
bisphenol A results in increased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
AGO2 |
argonaute RISC catalytic component 2 |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of AGO2 protein [bisphenol A co-treated with 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline] results in decreased expression of AGO2 protein |
CTD |
PMID:31266599 |
|
NCBI chr 4:2,966,794...3,012,388
Ensembl chr 4:2,919,511...3,015,334
|
|
G |
ALB |
albumin |
multiple interactions decreases expression |
EXP |
Cysteine inhibits the reaction [bisphenol A results in decreased expression of ALB protein] |
CTD |
PMID:37999554 |
|
NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696
|
|
G |
AQP3 |
aquaporin 3 |
decreases expression |
EXP |
bisphenol A results in decreased expression of AQP3 mRNA |
CTD |
PMID:32710935 |
|
NCBI chr10:33,045,374...33,050,285
Ensembl chr10:33,045,245...33,051,082
|
|
G |
AQP4 |
aquaporin 4 |
decreases expression |
EXP |
bisphenol A results in decreased expression of AQP4 mRNA |
CTD |
PMID:32710935 |
|
NCBI chr 6:111,407,632...111,422,169
Ensembl chr 6:111,407,639...111,422,109
|
|
G |
AQP9 |
aquaporin 9 |
affects expression |
EXP |
bisphenol A affects the expression of AQP9 mRNA |
CTD |
PMID:32710935 |
|
NCBI chr 1:113,798,380...113,848,452
Ensembl chr 1:113,794,040...113,848,683
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP |
Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of ATF4 protein] |
CTD |
PMID:37108405 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
ATF6 |
activating transcription factor 6 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of ATF6 protein Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of ATF6 protein] |
CTD |
PMID:37108405 |
|
NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of BAX mRNA; bisphenol A results in increased expression of BAX protein Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of BAX mRNA]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of BAX protein] |
CTD |
PMID:37108405 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of BCL2 mRNA; bisphenol A results in decreased expression of BCL2 protein Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of BCL2 mRNA]; Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein] |
CTD |
PMID:28819136 PMID:37108405 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of BCL2L1 mRNA; bisphenol A results in decreased expression of BCL2L1 protein Sodium Selenite affects the reaction [bisphenol A results in decreased expression of BCL2L1 protein] |
CTD |
PMID:28819136 PMID:37108405 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
BECN1 |
beclin 1 |
increases expression |
EXP |
bisphenol A results in increased expression of BECN1 mRNA |
CTD |
PMID:28819136 |
|
NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
|
|
G |
CARTPT |
CART prepropeptide |
increases expression decreases expression |
EXP |
bisphenol A results in increased expression of CARTPT protein bisphenol A results in decreased expression of CARTPT protein |
CTD |
PMID:29558425 PMID:29569701 PMID:29577965 PMID:29888781 PMID:38069115 |
|
NCBI chr16:48,043,558...48,045,592
Ensembl chr16:48,043,492...48,045,592
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression |
EXP |
[bisphenol A co-treated with fisetin] results in increased expression of CASP3 mRNA; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of CASP3 protein] bisphenol A results in increased expression of CASP3 mRNA; bisphenol A results in increased expression of CASP3 protein |
CTD |
PMID:29544186 PMID:37108405 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases expression |
EXP |
Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of CASP8 mRNA] |
CTD |
PMID:37108405 |
|
NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases expression |
EXP |
Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of CASP9 mRNA] |
CTD |
PMID:37108405 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CAT |
catalase |
multiple interactions decreases activity decreases expression |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; Sodium Selenite inhibits the reaction [bisphenol A results in decreased activity of CAT protein] |
CTD |
PMID:29129240 PMID:37108405 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
bisphenol A results in increased expression of CDKN1A protein |
CTD |
PMID:28819136 |
|
NCBI chr 7:32,354,776...32,363,771
Ensembl chr 7:32,359,455...32,363,761
|
|
G |
CLDN1 |
claudin 1 |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of CLDN1 mRNA; bisphenol A results in decreased expression of CLDN1 protein Cysteine inhibits the reaction [bisphenol A results in decreased expression of CLDN1 mRNA]; Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of CLDN1 protein] |
CTD |
PMID:37108405 PMID:37999554 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
multiple interactions decreases expression |
EXP |
[bisphenol A co-treated with fisetin] results in decreased expression of CYP11A1 mRNA; fisetin promotes the reaction [bisphenol A results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:29544186 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of CYP19A1 protein bisphenol A inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein] |
CTD |
PMID:28284726 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
DBH |
dopamine beta-hydroxylase |
increases expression |
EXP |
bisphenol A results in increased expression of DBH protein |
CTD |
PMID:29888781 |
|
NCBI chr 1:273,204,407...273,225,562
Ensembl chr 1:273,204,175...273,225,552
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of DDIT3 protein Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of DDIT3 protein] |
CTD |
PMID:37108405 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
DICER1 |
dicer 1, ribonuclease III |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of DICER1 mRNA; bisphenol A results in decreased expression of DICER1 protein 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [bisphenol A results in decreased expression of DICER1 protein]; [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with bisphenol A] results in decreased expression of DICER1 mRNA |
CTD |
PMID:31266599 |
|
NCBI chr 7:116,361,630...116,436,471
Ensembl chr 7:116,365,802...116,411,224
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
multiple interactions decreases expression |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA] |
CTD |
PMID:28445388 PMID:28819136 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
DNMT3B |
DNA methyltransferase 3 beta |
decreases expression |
EXP |
bisphenol A results in decreased expression of DNMT3B mRNA |
CTD |
PMID:28819136 |
|
NCBI chr17:36,345,715...36,386,076
Ensembl chr17:36,345,816...36,386,072
|
|
G |
DROSHA |
drosha ribonuclease III |
multiple interactions decreases expression |
EXP |
4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [bisphenol A results in decreased expression of DROSHA protein]; [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with bisphenol A] results in increased expression of DROSHA mRNA; bisphenol A inhibits the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of DROSHA protein] |
CTD |
PMID:31266599 |
|
NCBI chr16:17,727,695...17,847,954
Ensembl chr16:17,565,137...17,848,162
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
EXP |
Sodium Selenite inhibits the reaction [bisphenol A results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:37108405 |
|
NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of ERN1 protein Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of ERN1 protein] |
CTD |
PMID:37108405 |
|
NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
bisphenol A inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]; bisphenol A promotes the reaction [fisetin inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]]; fisetin promotes the reaction [bisphenol A inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]] |
CTD |
PMID:29544186 PMID:34019995 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
GAL |
galanin and GMAP prepropeptide |
increases expression affects expression |
EXP |
bisphenol A results in increased expression of GAL protein bisphenol A affects the expression of GAL protein |
CTD |
PMID:29558425 PMID:29569701 PMID:29577965 PMID:29888781 PMID:38069115 |
|
NCBI chr 2:4,351,113...4,357,167
Ensembl chr 2:4,351,113...4,356,647
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions increases expression |
EXP |
Cysteine inhibits the reaction [bisphenol A results in increased expression of GCLC mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of GCLM mRNA Cysteine inhibits the reaction [bisphenol A results in increased expression of GCLM mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr 4:123,371,198...123,390,130
Ensembl chr 4:123,371,193...123,390,131
|
|
G |
GPER1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
EXP |
[bisphenol A co-treated with 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline] results in decreased expression of GPER1 protein |
CTD |
PMID:31266599 |
|
NCBI chr 3:711,427...715,982
Ensembl chr 3:712,160...715,980
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP |
[bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA bisphenol A results in decreased expression of GPX1 mRNA |
CTD |
PMID:28819136 PMID:29129240 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GYS1 |
glycogen synthase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter |
CTD |
PMID:29065941 |
|
NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261
|
|
G |
HMOX1 |
heme oxygenase 1 |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of HMOX1 mRNA Cysteine inhibits the reaction [bisphenol A results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:37999554 |
|
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions decreases expression |
EXP |
bisphenol A promotes the reaction [fisetin results in decreased expression of HSD3B1 mRNA]; fisetin promotes the reaction [bisphenol A results in decreased expression of HSD3B1 mRNA] |
CTD |
PMID:29544186 |
|
NCBI chr 4:101,565,229...101,574,110
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of HSPA5 protein Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of HSPA5 protein] |
CTD |
PMID:37108405 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
IFNG |
interferon gamma |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of IFNG mRNA Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IFNG mRNA] |
CTD |
PMID:37108405 PMID:38154151 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IGF1 |
insulin like growth factor 1 |
decreases expression |
EXP |
bisphenol A results in decreased expression of IGF1 mRNA |
CTD |
PMID:32710935 |
|
NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
decreases expression |
EXP |
bisphenol A results in decreased expression of IGF1R mRNA |
CTD |
PMID:32710935 |
|
NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,825...137,691,058
|
|
G |
IL10 |
interleukin 10 |
multiple interactions decreases expression decreases secretion |
EXP |
Glutamine inhibits the reaction [bisphenol A results in decreased secretion of IL10 protein]; Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] |
CTD |
PMID:37108405 PMID:38154151 |
|
NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378
|
|
G |
IL17A |
interleukin 17A |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of IL17A mRNA Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IL17A mRNA] |
CTD |
PMID:37108405 |
|
NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153
|
|
G |
IL6 |
interleukin 6 |
multiple interactions increases secretion increases expression |
EXP |
Glutamine inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased secretion of IL6 protein]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA] |
CTD |
PMID:37108405 PMID:38154151 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of KEAP1 mRNA Cysteine inhibits the reaction [bisphenol A results in increased expression of KEAP1 mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr 2:69,280,940...69,290,267
Ensembl chr 2:69,276,336...69,294,382
|
|
G |
LDHA |
lactate dehydrogenase A |
increases expression multiple interactions decreases methylation |
EXP |
bisphenol A results in increased expression of LDHA mRNA [bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter bisphenol A results in decreased methylation of LDHA promoter |
CTD |
PMID:29065941 |
|
NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
|
|
G |
LOC100623720 |
collagen alpha-1(VI) chain |
multiple interactions decreases expression |
EXP |
bisphenol A inhibits the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of COL6A1 protein] bisphenol A results in decreased expression of COL6A1 protein |
CTD |
PMID:31266599 |
|
NCBI chr13:208,295,245...208,321,789
Ensembl chr13:208,295,451...208,313,127
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
increases expression multiple interactions increases secretion |
EXP |
bisphenol A results in increased expression of IL1B mRNA; bisphenol A results in increased expression of IL1B protein Glutamine inhibits the reaction [bisphenol A results in increased secretion of IL1B protein]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA] |
CTD |
PMID:29558425 PMID:37108405 PMID:38154151 |
|
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression |
EXP |
bisphenol A results in increased expression of MAP1LC3B protein |
CTD |
PMID:31266599 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
MAP3K7 |
mitogen-activated protein kinase kinase kinase 7 |
affects expression |
EXP |
bisphenol A affects the expression of MAP3K7 protein |
CTD |
PMID:29577965 |
|
NCBI chr 1:58,482,046...58,548,087
Ensembl chr 1:58,481,956...58,548,057
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of MYD88 mRNA Glutamine inhibits the reaction [bisphenol A results in increased expression of MYD88 mRNA] |
CTD |
PMID:38154151 |
|
NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
|
|
G |
NANOG |
Nanog homeobox |
decreases expression |
EXP |
bisphenol A results in decreased expression of NANOG mRNA |
CTD |
PMID:28819136 |
|
NCBI chr 5:62,931,642...62,939,086
Ensembl chr 5:62,932,382...62,939,082
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of NFKB1 mRNA Glutamine inhibits the reaction [bisphenol A results in increased expression of NFKB1 mRNA] |
CTD |
PMID:38154151 |
|
NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691
|
|
G |
NOS1 |
nitric oxide synthase 1 |
increases expression |
EXP |
bisphenol A results in increased expression of NOS1 protein |
CTD |
PMID:38069115 |
|
NCBI chr14:35,112,898...35,299,297
Ensembl chr14:35,113,184...35,295,944
|
|
G |
NOX1 |
NADPH oxidase 1 |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of NOX1 mRNA Cysteine inhibits the reaction [bisphenol A results in decreased expression of NOX1 mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr X:82,540,664...82,575,811
Ensembl chr X:82,540,667...82,586,532
|
|
G |
OCLN |
occludin |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of OCLN protein Sodium Selenite affects the reaction [bisphenol A results in decreased expression of OCLN protein] |
CTD |
PMID:37108405 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
PLIN1 |
perilipin 1 |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of PLIN1 protein [bisphenol A co-treated with 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline] results in increased expression of PLIN1 protein |
CTD |
PMID:31266599 |
|
NCBI chr 7:55,237,517...55,250,797
Ensembl chr 7:55,236,348...55,250,797
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
decreases expression |
EXP |
bisphenol A results in decreased expression of POU5F1 mRNA; bisphenol A results in decreased expression of POU5F1 protein |
CTD |
PMID:28819136 |
|
NCBI chr 7:23,564,654...23,570,691
|
|
G |
PPP1R16A |
protein phosphatase 1 regulatory subunit 16A |
increases activity multiple interactions |
EXP |
bisphenol A results in increased activity of GPT protein Cysteine inhibits the reaction [bisphenol A results in increased activity of GPT protein] |
CTD |
PMID:37999554 |
|
NCBI chr 4:302,621...320,048
Ensembl chr 4:297,748...320,056
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
increases expression multiple interactions |
EXP |
bisphenol A results in increased expression of RELA protein Glutamine inhibits the reaction [bisphenol A results in increased expression of RELA protein] |
CTD |
PMID:38154151 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
SDHA |
succinate dehydrogenase complex flavoprotein subunit A |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of SDHA mRNA Cysteine inhibits the reaction [bisphenol A results in decreased expression of SDHA mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr16:79,838,442...79,862,956
Ensembl chr16:79,834,044...79,862,524
|
|
G |
SI |
sucrase-isomaltase |
decreases expression |
EXP |
bisphenol A results in decreased expression of SI mRNA |
CTD |
PMID:28445388 |
|
NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
decreases expression decreases methylation multiple interactions |
EXP |
bisphenol A results in decreased expression of SLC15A1 mRNA bisphenol A results in decreased methylation of SLC15A1 promoter [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter] |
CTD |
PMID:28445388 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC18A3 |
solute carrier family 18 member A3 |
decreases expression |
EXP |
bisphenol A results in decreased expression of SLC18A3 protein |
CTD |
PMID:29558425 PMID:29577965 |
|
NCBI chr14:90,113,534...90,115,813
Ensembl chr14:90,113,844...90,115,430
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
G |
SLC7A1 |
solute carrier family 7 member 1 |
increases expression |
EXP |
bisphenol A results in increased expression of SLC7A1 mRNA |
CTD |
PMID:32710935 |
|
NCBI chr11:6,538,053...6,604,654
Ensembl chr11:6,538,045...6,604,658
|
|
G |
SLC7A7 |
solute carrier family 7 member 7 |
decreases expression |
EXP |
bisphenol A results in decreased expression of SLC7A7 mRNA |
CTD |
PMID:32710935 |
|
NCBI chr 7:76,195,774...76,235,406
Ensembl chr 7:76,198,256...76,235,402
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases expression |
EXP |
bisphenol A results in decreased expression of SOD1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
bisphenol A results in decreased expression of SOD2 mRNA Cysteine inhibits the reaction [bisphenol A results in decreased expression of SOD2 mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
G |
SOX2 |
SRY-box transcription factor 2 |
decreases expression |
EXP |
bisphenol A results in decreased expression of SOX2 mRNA |
CTD |
PMID:28819136 |
|
NCBI chr13:119,668,476...119,669,435
Ensembl chr13:119,668,476...119,669,435
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions decreases expression |
EXP |
[bisphenol A co-treated with fisetin] results in decreased expression of STAR mRNA; fisetin promotes the reaction [bisphenol A results in decreased expression of STAR mRNA] |
CTD |
PMID:29544186 |
|
NCBI chr15:48,377,597...48,385,398
Ensembl chr15:48,377,521...48,385,462
|
|
G |
TAC1 |
tachykinin precursor 1 |
increases expression |
EXP |
bisphenol A results in increased expression of TAC1 protein |
CTD |
PMID:29558425 PMID:29569701 PMID:29888781 PMID:38069115 |
|
NCBI chr 9:77,197,403...77,206,529
Ensembl chr 9:77,197,536...77,206,523
|
|
G |
TFAM |
transcription factor A, mitochondrial |
decreases expression |
EXP |
bisphenol A results in decreased expression of TFAM mRNA |
CTD |
PMID:28819136 |
|
NCBI chr14:92,261,713...92,279,731
Ensembl chr14:92,259,403...92,279,731
|
|
G |
TFF3 |
trefoil factor 3 |
multiple interactions decreases expression |
EXP |
Glutamine inhibits the reaction [bisphenol A results in decreased expression of TFF3 protein] |
CTD |
PMID:38154151 |
|
NCBI chr13:205,641,038...205,644,333
Ensembl chr13:205,641,038...205,644,333
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions decreases expression |
EXP |
Sodium Selenite affects the reaction [bisphenol A results in decreased expression of TJP1 protein] |
CTD |
PMID:37108405 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TJP2 |
tight junction protein 2 |
multiple interactions decreases expression |
EXP |
Cysteine inhibits the reaction [bisphenol A results in decreased expression of TJP2 mRNA] |
CTD |
PMID:37999554 |
|
NCBI chr 1:222,474,518...222,612,989
Ensembl chr 1:222,474,639...222,612,983
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions increases expression |
EXP |
Glutamine inhibits the reaction [bisphenol A results in increased expression of TLR4 mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased expression of TLR4 protein] bisphenol A results in increased expression of TLR4 mRNA; bisphenol A results in increased expression of TLR4 protein |
CTD |
PMID:38154151 |
|
NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970
|
|
G |
TNF |
tumor necrosis factor |
increases expression increases secretion multiple interactions |
EXP |
bisphenol A results in increased expression of TNF mRNA; bisphenol A results in increased expression of TNF protein bisphenol A results in increased secretion of TNF protein Glutamine inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased secretion of TNF protein]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of TNF mRNA] |
CTD |
PMID:29558425 PMID:37108405 PMID:38154151 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
TP53 |
tumor protein p53 |
increases expression |
EXP |
bisphenol A results in increased expression of TP53 protein |
CTD |
PMID:28819136 |
|
NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
EXP |
bisphenol A results in increased expression of VEGFA protein |
CTD |
PMID:20172683 |
|
NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366
|
|
G |
VIP |
vasoactive intestinal peptide |
decreases expression increases expression |
EXP |
bisphenol A results in decreased expression of VIP protein bisphenol A results in increased expression of VIP protein |
CTD |
PMID:29558425 PMID:29577965 |
|
NCBI chr 1:13,611,786...13,620,250
Ensembl chr 1:13,611,311...13,620,269
|
|
G |
XPO5 |
exportin 5 |
multiple interactions decreases expression |
EXP |
[4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with bisphenol A] results in decreased expression of XPO5 mRNA; [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline co-treated with bisphenol A] results in decreased expression of XPO5 protein bisphenol A results in decreased expression of XPO5 mRNA; bisphenol A results in decreased expression of XPO5 protein |
CTD |
PMID:31266599 |
|
NCBI chr 7:38,530,704...38,569,558
Ensembl chr 7:38,531,919...38,569,582
|
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,589,045...79,649,644
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,004
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,164,277...25,208,311
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein]] |
CTD |
PMID:19474210 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane binds to and results in decreased activity of PPARG protein; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Troglitazone results in increased activity of PPARG protein] |
CTD |
PMID:14506076 PMID:14519784 PMID:30481989 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] |
CTD |
PMID:30481989 |
|
NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased expression of TNF mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased expression of TNF protein] |
CTD |
PMID:17217567 PMID:19474210 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
4,4'-bisphenol F inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone] |
CTD |
PMID:34019995 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
increases expression |
EXP |
4,4'-bisphenol F results in increased expression of MMP9 mRNA |
CTD |
PMID:34019995 |
|
NCBI chr17:48,179,690...48,186,782
Ensembl chr17:48,179,671...48,186,788
|
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
EXP |
Brimonidine Tartrate results in increased phosphorylation of CREB1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:17680988 |
|
NCBI chr15:110,705,548...110,773,037
Ensembl chr15:110,705,496...110,771,728
|
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Bucladesine results in increased expression of ATP1A1 protein |
CTD |
PMID:28438630 |
|
NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,508...104,384,547
|
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATM protein] |
CTD |
PMID:38104654 |
|
NCBI chr 9:36,620,656...36,759,555
Ensembl chr 9:36,620,658...36,759,552
|
|
G |
CCNB1 |
cyclin B1 |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CCNB1 protein] |
CTD |
PMID:38104654 |
|
NCBI chr16:47,338,239...47,348,385
Ensembl chr16:47,338,110...47,348,377
|
|
G |
CDC25C |
cell division cycle 25C |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CDC25C protein] |
CTD |
PMID:38104654 |
|
NCBI chr 2:140,289,156...140,323,696
Ensembl chr 2:140,289,115...140,324,425
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CDK1 protein] |
CTD |
PMID:38104654 |
|
NCBI chr14:64,233,945...64,255,290
Ensembl chr14:64,233,987...64,372,197
|
|
G |
CHEK2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:38104654 |
|
NCBI chr14:45,699,833...45,967,350
Ensembl chr14:45,929,715...45,967,290
|
|
G |
RYR1 |
ryanodine receptor 1 |
increases activity multiple interactions |
EXP |
Caffeine results in increased activity of RYR1 protein; Caffeine results in increased activity of RYR1 protein mutant form Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]; Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein mutant form]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein] |
CTD |
PMID:11278295 |
|
NCBI chr 6:47,339,759...47,458,457
Ensembl chr 6:47,343,768...47,458,458
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
calphostin C inhibits the reaction [Clofibrate results in increased expression of NOS3 protein] |
CTD |
PMID:17105827 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
EXP |
calphostin C results in decreased expression of PPARA calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA protein]; calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA]; calphostin C promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of PPARA] |
CTD |
PMID:17105827 PMID:20568414 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
multiple interactions |
EXP |
capsazepine inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]] |
CTD |
PMID:18230619 |
|
NCBI chr12:49,676,536...49,709,634
Ensembl chr12:49,677,291...49,713,977
|
|
|
G |
RYR1 |
ryanodine receptor 1 |
increases activity |
EXP |
carvacrol results in increased activity of RYR1 protein |
CTD |
PMID:17641978 |
|
NCBI chr 6:47,339,759...47,458,457
Ensembl chr 6:47,343,768...47,458,458
|
|
|
G |
COMT |
catechol-O-methyltransferase |
multiple interactions |
EXP |
[S-Adenosylmethionine analog co-treated with COMT protein] results in increased methylation of catechol |
CTD |
PMID:20196537 |
|
NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998
|
|
|
G |
GPX4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [Diquat results in decreased expression of GPX4 mRNA] |
CTD |
PMID:38567716 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
|
G |
COMT |
catechol-O-methyltransferase |
decreases activity |
EXP |
Chlorogenic Acid results in decreased activity of COMT protein |
CTD |
PMID:27270453 |
|
NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:27861533 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein] |
CTD |
PMID:30287338 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [CPG-oligonucleotide results in increased expression of HSPD1 protein] |
CTD |
PMID:17727805 |
|
NCBI chr15:101,360,355...101,373,498
Ensembl chr15:101,360,094...101,373,526
|
|
G |
IFIT3 |
interferon induced protein with tetratricopeptide repeats 3 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IFIT1 mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr14:101,237,403...101,249,486
Ensembl chr14:101,237,571...101,249,498
|
|
G |
IFNB1 |
interferon beta 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IFNB1 mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr 1:201,850,935...201,851,495
Ensembl chr 1:201,850,935...201,851,495
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IFNG mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IL12B |
interleukin 12B |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IL12B mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr16:64,143,268...64,158,929
Ensembl chr16:64,143,268...64,158,929
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IL6 mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
IRF7 |
interferon regulatory factor 7 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IRF7 mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr 2:372,235...375,572
Ensembl chr 2:372,238...375,378
|
|
G |
ISG15 |
ISG15 ubiquitin like modifier |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of ISG15 mRNA] |
CTD |
PMID:27079946 |
|
NCBI chr 6:63,363,201...63,364,211
Ensembl chr 6:63,363,173...63,364,208
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of IL1B mRNA] |
CTD |
PMID:27079946 |
|
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] |
CTD |
PMID:30287338 |
|
NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [SZU-101 results in increased expression of RELA protein] |
CTD |
PMID:27079946 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
G |
SQSTM1 |
sequestosome 1 |
increases expression multiple interactions |
EXP |
Chloroquine results in increased expression of SQSTM1 protein Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein] |
CTD |
PMID:30287338 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TLR7 |
toll like receptor 7 |
multiple interactions |
EXP |
Chloroquine affects the localization of and results in decreased activity of TLR7 protein |
CTD |
PMID:27079946 |
|
NCBI chr X:9,573,178...9,576,987
|
|
|
G |
CYP2B6B |
cytochrome P450 family 2 subfamily B member 6B |
decreases response to substance |
EXP |
CYP2B6B protein results in decreased susceptibility to chlortoluron |
CTD |
PMID:16315095 |
|
NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,334
|
|
G |
CYP2C49 |
cytochrome P450 2C49 |
decreases response to substance |
EXP |
CYP2C49 protein results in decreased susceptibility to chlortoluron |
CTD |
PMID:16315095 |
|
NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions increases uptake |
EXP |
Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
GUCY1A1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
BAY 58-2667 inhibits the reaction [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased degradation of GUCY1A1 protein] |
CTD |
PMID:19466990 |
|
NCBI chr 8:44,448,758...44,520,737
Ensembl chr 8:44,449,290...44,518,135
|
|
G |
GUCY1B1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
EXP |
BAY 58-2667 inhibits the reaction [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased degradation of GUCY1B1 protein] |
CTD |
PMID:19466990 |
|
NCBI chr 8:44,544,364...44,604,690
Ensembl chr 8:44,544,179...44,604,687
|
|
|
G |
ACO1 |
aconitase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ACO1 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr10:33,937,833...34,001,895
Ensembl chr10:33,937,833...34,001,900
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of ACOX1 mRNA |
CTD |
PMID:16896063 PMID:17437637 |
|
NCBI chr12:5,450,913...5,479,550
Ensembl chr12:5,439,361...5,479,546
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
|
|
G |
ALB |
albumin |
decreases expression |
EXP |
Clofibrate results in decreased expression of ALB mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Clofibrate results in increased expression of BAX mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
CAT |
catalase |
increases expression |
EXP |
Clofibrate results in increased expression of CAT mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Clofibrate results in increased expression of CPT1A mRNA |
CTD |
PMID:16896063 PMID:17363680 |
|
NCBI chr 2:4,250,642...4,293,914
Ensembl chr 2:4,233,099...4,293,911
|
|
G |
CTSB |
cathepsin B |
increases expression |
EXP |
Clofibrate results in increased expression of CTSB mRNA |
CTD |
PMID:16896063 |
|
NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,033,877
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
decreases expression |
EXP |
Clofibrate results in decreased expression of DIO2 mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 7:103,096,414...103,110,749
Ensembl chr 7:103,096,433...103,323,258
|
|
G |
EDN1 |
endothelin 1 |
decreases expression multiple interactions |
EXP |
Clofibrate results in decreased expression of EDN1 protein Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein]; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in decreased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Clofibrate results in increased expression of FABP1 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr 3:57,850,511...57,854,966
Ensembl chr 3:57,850,499...57,854,956
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Clofibrate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
HMGCS2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
EXP |
Clofibrate results in increased expression of HMGCS2 mRNA |
CTD |
PMID:17363680 |
|
NCBI chr 4:101,420,941...101,440,302
Ensembl chr 4:101,420,872...101,438,126
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Clofibrate results in increased expression of JUN mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 6:153,686,425...153,687,635
Ensembl chr 6:153,685,682...153,687,636
|
|
G |
KNG1 |
kininogen 1 |
multiple interactions |
EXP |
Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:17105827 |
|
NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
Clofibrate results in increased expression of MYC mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression multiple interactions |
EXP |
Clofibrate results in increased expression of NOS3 protein calphostin C inhibits the reaction [Clofibrate results in increased expression of NOS3 protein] |
CTD |
PMID:17105827 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
EXP |
Clofibrate results in increased expression of PPARA; Clofibrate results in increased expression of PPARA protein calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA protein]; calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA] |
CTD |
PMID:17105827 PMID:20568414 |
|
NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression |
EXP |
Clofibrate results in increased expression of SCD mRNA |
CTD |
PMID:17363680 |
|
NCBI chr14:111,461,560...111,478,033
Ensembl chr14:111,461,569...111,478,020
|
|
G |
SLC5A5 |
solute carrier family 5 member 5 |
increases expression |
EXP |
Clofibrate results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression |
EXP |
Clofibrate results in increased expression of SOD1 mRNA |
CTD |
PMID:17437637 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
THRA |
thyroid hormone receptor alpha |
decreases expression |
EXP |
Clofibrate results in decreased expression of THRA mRNA |
CTD |
PMID:16896063 |
|
NCBI chr12:22,270,506...22,296,684
Ensembl chr12:22,270,062...22,296,618
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
Clofibrate results in decreased expression of TNF mRNA |
CTD |
PMID:17437637 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
TPO |
thyroid peroxidase |
increases expression |
EXP |
Clofibrate results in increased expression of TPO mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208
|
|
G |
TSHR |
thyroid stimulating hormone receptor |
increases expression |
EXP |
Clofibrate results in increased expression of TSHR mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 7:103,768,260...103,925,777
Ensembl chr 7:103,768,296...103,925,922
|
|
G |
TTR |
transthyretin |
decreases expression |
EXP |
Clofibrate results in decreased expression of TTR mRNA |
CTD |
PMID:16896063 |
|
NCBI chr 6:115,496,338...115,503,974
Ensembl chr 6:115,496,326...115,503,977
|
|
|
G |
MAOA |
monoamine oxidase A |
decreases activity |
EXP |
Clorgyline analog results in decreased activity of MAOA protein |
CTD |
PMID:33359020 |
|
NCBI chr X:38,930,452...39,006,220
|
|
|
G |
EDN1 |
endothelin 1 |
increases expression multiple interactions |
EXP |
Cocaine results in increased expression of EDN1 protein 1,3-ditolylguanidine inhibits the reaction [Cocaine results in increased expression of EDN1 protein]; Haloperidol inhibits the reaction [Cocaine results in increased expression of EDN1 protein] |
CTD |
PMID:9714087 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
CYP2A19 |
cytochrome P450 family 2 subfamily A member 19 |
increases hydroxylation multiple interactions |
EXP |
CYP2A19 protein results in increased hydroxylation of coumarin 2-aminoacetophenone inhibits the reaction [[CYP2A19 protein results in increased hydroxylation of coumarin] which results in increased chemical synthesis of 7-hydroxycoumarin]; 2-aminoacetophenone inhibits the reaction [CYP2A19 protein results in increased hydroxylation of coumarin]; [CYP2A19 protein results in increased hydroxylation of coumarin] which results in increased chemical synthesis of 7-hydroxycoumarin; Skatole inhibits the reaction [[CYP2A19 protein results in increased hydroxylation of coumarin] which results in increased chemical synthesis of 7-hydroxycoumarin]; Skatole inhibits the reaction [CYP2A19 protein results in increased hydroxylation of coumarin] |
CTD |
PMID:30599194 |
|
NCBI chr 6:49,056,579...49,064,111
Ensembl chr 6:49,056,578...49,064,107
|
|
|
G |
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
decreases activity |
EXP |
Crizotinib results in decreased activity of NTRK1 protein |
CTD |
PMID:21812414 |
|
NCBI chr 4:93,219,509...93,237,944
Ensembl chr 4:93,219,516...93,255,981
|
|
G |
NTRK2 |
neurotrophic receptor tyrosine kinase 2 |
decreases activity |
EXP |
Crizotinib results in decreased activity of NTRK2 protein |
CTD |
PMID:21812414 |
|
NCBI chr10:30,030,050...30,429,938
Ensembl chr10:30,033,405...30,429,882
|
|
|
G |
ACO2 |
aconitase 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [maleic acid results in decreased activity of ACO2 protein] |
CTD |
PMID:25119790 |
|
NCBI chr 5:7,014,383...7,071,023
Ensembl chr 5:7,008,719...7,071,025
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein |
CTD |
PMID:29129240 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
MTHFR |
methylenetetrahydrofolate reductase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
|
|
G |
SI |
sucrase-isomaltase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA |
CTD |
PMID:28445388 |
|
NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
|
G |
ESR1 |
estrogen receptor 1 |
increases expression |
EXP |
daidzein results in increased expression of ESR1 mRNA |
CTD |
PMID:19617652 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
ESR2 |
estrogen receptor 2 |
increases expression |
EXP |
daidzein results in increased expression of ESR2 mRNA; daidzein results in increased expression of ESR2 protein |
CTD |
PMID:19617652 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
daidzein inhibits the reaction [LHB protein results in increased abundance of Progesterone] |
CTD |
PMID:19617652 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Penicillins]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
decreases expression multiple interactions |
EXP |
Dichlorodiphenyl Dichloroethylene results in decreased expression of CYP11A1 mRNA Dichlorodiphenyl Dichloroethylene inhibits the reaction [Cholera Toxin results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:11226075 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
increases activity |
EXP |
Dichlorodiphenyl Dichloroethylene results in increased activity of CYP19A1 protein |
CTD |
PMID:18195494 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of AKT1 protein |
CTD |
PMID:37353039 |
|
|
|
G |
PDK1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PDK1 protein |
CTD |
PMID:37353039 |
|
NCBI chr15:78,608,394...78,650,958
Ensembl chr15:78,608,432...78,652,962
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PIK3R1 protein |
CTD |
PMID:37353039 |
|
NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,511,521...46,523,609
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PTEN protein |
CTD |
PMID:37353039 |
|
NCBI chr14:99,929,590...100,021,619
|
|
|
G |
ACHE |
acetylcholinesterase |
decreases activity |
EXP |
Diazinon results in decreased activity of ACHE protein |
CTD |
PMID:21467751 |
|
NCBI chr 3:8,732,451...8,738,274
Ensembl chr 3:8,732,441...8,738,605
|
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
Dicumarol inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]] |
CTD |
PMID:20732396 |
|
NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590
|
|
|
G |
CAT |
catalase |
affects activity decreases activity multiple interactions decreases expression |
EXP |
Diquat affects the activity of CAT protein Diquat results in decreased activity of CAT protein 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Diquat results in decreased activity of CAT protein]; [Zinc binds to alpha-hydroxy-gamma-methylmercaptobutyric acid] inhibits the reaction [Diquat results in decreased expression of CAT mRNA] |
CTD |
PMID:22558963 PMID:32280687 PMID:38567716 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CLDN1 |
claudin 1 |
decreases expression |
EXP |
Diquat results in decreased expression of CLDN1 protein |
CTD |
PMID:26338884 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CLDN3 |
claudin 3 |
decreases expression multiple interactions |
EXP |
Diquat results in decreased expression of CLDN3 protein Amino Acids inhibits the reaction [Diquat results in decreased expression of CLDN3 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,073...11,020,102
|
|
G |
CLDN4 |
claudin 4 |
decreases expression multiple interactions |
EXP |
Diquat results in decreased expression of CLDN4 protein Amino Acids inhibits the reaction [Diquat results in decreased expression of CLDN4 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 3:11,039,711...11,053,930
Ensembl chr 3:11,039,706...11,053,925
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
Diquat results in increased expression of DDIT3 protein |
CTD |
PMID:38567716 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation |
EXP |
Diquat results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:38567716 |
|
NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
Diquat results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:38567716 |
|
NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP |
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA]; [Zinc binds to alpha-hydroxy-gamma-methylmercaptobutyric acid] inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA]; Zinc Sulfate inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA] |
CTD |
PMID:32280687 PMID:38567716 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GPX4 |
glutathione peroxidase 4 |
decreases expression multiple interactions |
EXP |
Diquat results in decreased expression of GPX4 mRNA 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Diquat results in decreased expression of GPX4 mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [Diquat results in decreased expression of GPX4 mRNA] |
CTD |
PMID:38567716 |
|
NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Diquat results in increased expression of HSPA5 protein |
CTD |
PMID:38567716 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
increases expression multiple interactions |
EXP |
Diquat results in increased expression of IL1B mRNA [Zinc binds to alpha-hydroxy-gamma-methylmercaptobutyric acid] inhibits the reaction [Diquat results in increased expression of IL1B mRNA]; Zinc Sulfate inhibits the reaction [Diquat results in increased expression of IL1B mRNA] |
CTD |
PMID:32280687 |
|
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
decreases expression multiple interactions |
EXP |
Diquat results in decreased expression of NFE2L2 mRNA [Zinc binds to alpha-hydroxy-gamma-methylmercaptobutyric acid] inhibits the reaction [Diquat results in decreased expression of NFE2L2 mRNA]; Zinc Sulfate inhibits the reaction [Diquat results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:32280687 |
|
NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183
|
|
G |
OCLN |
occludin |
increases expression |
EXP |
Diquat results in increased expression of OCLN protein |
CTD |
PMID:26338884 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
PPP1R16A |
protein phosphatase 1 regulatory subunit 16A |
increases activity |
EXP |
Diquat results in increased activity of GPT protein |
CTD |
PMID:38567716 |
|
NCBI chr 4:302,621...320,048
Ensembl chr 4:297,748...320,056
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Diquat results in decreased expression of SOD1 mRNA]; [Zinc binds to alpha-hydroxy-gamma-methylmercaptobutyric acid] inhibits the reaction [Diquat results in decreased expression of SOD1 mRNA]; Zinc Sulfate inhibits the reaction [Diquat results in decreased expression of SOD1 mRNA] |
CTD |
PMID:32280687 PMID:38567716 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
TDO2 |
tryptophan 2,3-dioxygenase |
increases expression |
EXP |
Diquat results in increased expression of TDO2 mRNA |
CTD |
PMID:22558963 |
|
NCBI chr 8:44,708,722...44,725,954
Ensembl chr 8:44,708,746...44,740,962
|
|
G |
TJP1 |
tight junction protein 1 |
decreases expression |
EXP |
Diquat results in decreased expression of TJP1 protein |
CTD |
PMID:26338884 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TJP2 |
tight junction protein 2 |
multiple interactions decreases expression |
EXP |
Amino Acids inhibits the reaction [Diquat results in decreased expression of TJP2 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 1:222,474,518...222,612,989
Ensembl chr 1:222,474,639...222,612,983
|
|
G |
TJP3 |
tight junction protein 3 |
decreases expression multiple interactions |
EXP |
Diquat results in decreased expression of TJP3 protein Amino Acids inhibits the reaction [Diquat results in decreased expression of TJP3 protein] |
CTD |
PMID:26338884 |
|
NCBI chr 2:74,938,153...74,971,431
Ensembl chr 2:74,938,152...74,971,531
|
|
G |
TNF |
tumor necrosis factor |
increases expression multiple interactions |
EXP |
Diquat results in increased expression of TNF mRNA [Zinc binds to alpha-hydroxy-gamma-methylmercaptobutyric acid] inhibits the reaction [Diquat results in increased expression of TNF mRNA]; Zinc Sulfate inhibits the reaction [Diquat results in increased expression of TNF mRNA] |
CTD |
PMID:32280687 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
HK2 |
hexokinase 2 |
decreases expression |
EXP |
Dobutamine results in decreased expression of HK2 protein |
CTD |
PMID:19944370 |
|
NCBI chr 3:68,155,656...68,231,187
Ensembl chr 3:68,153,835...68,231,615
|
|
G |
NOS2 |
nitric oxide synthase 2 |
affects response to substance |
EXP |
NOS2 protein affects the susceptibility to Dobutamine |
CTD |
PMID:20141602 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
PYGM |
glycogen phosphorylase, muscle associated |
decreases expression |
EXP |
Dobutamine results in decreased expression of PYGM protein |
CTD |
PMID:19944370 |
|
NCBI chr 2:7,409,330...7,421,256
Ensembl chr 2:7,409,116...7,421,254
|
|
|
G |
GJA1 |
gap junction protein alpha 1 |
decreases expression |
EXP |
Doxorubicin results in decreased expression of GJA1 protein |
CTD |
PMID:32877659 |
|
NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
increases activity increases expression |
EXP |
Doxorubicin results in increased activity of MMP1 protein Doxorubicin results in increased expression of MMP1 mRNA |
CTD |
PMID:19782292 |
|
NCBI chr 9:33,411,738...33,420,205
Ensembl chr 9:33,411,065...33,420,076
|
|
G |
MMP14 |
matrix metallopeptidase 14 |
increases expression increases activity |
EXP |
Doxorubicin results in increased expression of MMP14 mRNA Doxorubicin results in increased activity of MMP14 protein |
CTD |
PMID:19782292 |
|
NCBI chr 7:76,174,502...76,185,931
Ensembl chr 7:76,172,971...76,185,928
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
increases expression increases activity |
EXP |
Doxorubicin results in increased expression of MMP2 mRNA Doxorubicin results in increased activity of MMP2 protein |
CTD |
PMID:19782292 |
|
NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,595...30,086,982
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
increases expression increases activity |
EXP |
Doxorubicin results in increased expression of MMP9 mRNA Doxorubicin results in increased activity of MMP9 protein |
CTD |
PMID:19782292 |
|
NCBI chr17:48,179,690...48,186,782
Ensembl chr17:48,179,671...48,186,788
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
Doxorubicin results in decreased expression of TNF mRNA |
CTD |
PMID:15810080 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
TNNT2 |
troponin T2, cardiac type |
decreases expression |
EXP |
Doxorubicin results in decreased expression of TNNT2 protein |
CTD |
PMID:32877659 |
|
NCBI chr10:23,749,528...23,759,696
Ensembl chr10:23,749,335...23,763,396
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
increases uptake multiple interactions |
EXP |
SLCO1A2 protein results in increased uptake of Doxycycline Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
increases expression |
EXP |
esculetin results in increased expression of CYP1A2 mRNA |
CTD |
PMID:24176340 |
|
NCBI chr 7:58,779,529...58,786,155
Ensembl chr 7:58,779,475...58,786,100
|
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
increases uptake multiple interactions |
EXP |
SLCO1A2 protein results in increased uptake of estrone sulfate Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; cefquinome inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Clarithromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Erythromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Penicillins inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
affects localization |
EXP |
Fenofibrate affects the localization of ABCA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 1:246,144,277...246,278,492
Ensembl chr 1:246,144,277...246,278,492
|
|
G |
APOA1 |
apolipoprotein A1 |
increases secretion decreases expression multiple interactions |
EXP |
Fenofibrate results in increased secretion of APOA1 protein Fenofibrate results in decreased expression of APOA1 mRNA Fenofibrate inhibits the reaction [APOA1 protein results in increased transport of Cholesterol]; Fenofibrate promotes the reaction [APOA1 protein results in increased transport of Cholesterol] |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
affects localization |
EXP |
Fenofibrate affects the localization of SCARB1 protein |
CTD |
PMID:16530456 |
|
NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,568
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
[Fenofibrate co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein] |
CTD |
PMID:15226458 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases metabolic processing multiple interactions |
EXP |
HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide; chromium mesoporphyrin inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]; tin protoporphyrin IX inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide] |
CTD |
PMID:16751286 |
|
|
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[bisphenol A co-treated with fisetin] results in increased expression of CASP3 mRNA |
CTD |
PMID:29544186 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
multiple interactions |
EXP |
[bisphenol A co-treated with fisetin] results in decreased expression of CYP11A1 mRNA; fisetin promotes the reaction [bisphenol A results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:29544186 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
bisphenol A promotes the reaction [fisetin inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]]; fisetin inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]; fisetin promotes the reaction [bisphenol A inhibits the reaction [FSHB protein results in increased chemical synthesis of and results in increased secretion of Progesterone]] |
CTD |
PMID:29544186 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions decreases expression |
EXP |
bisphenol A promotes the reaction [fisetin results in decreased expression of HSD3B1 mRNA]; fisetin promotes the reaction [bisphenol A results in decreased expression of HSD3B1 mRNA] |
CTD |
PMID:29544186 |
|
NCBI chr 4:101,565,229...101,574,110
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
[bisphenol A co-treated with fisetin] results in decreased expression of STAR mRNA; fisetin promotes the reaction [bisphenol A results in decreased expression of STAR mRNA] |
CTD |
PMID:29544186 |
|
NCBI chr15:48,377,597...48,385,398
Ensembl chr15:48,377,521...48,385,462
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Flavones co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein |
CTD |
PMID:31669396 |
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Flavones inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:31669396 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Flavones inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein] |
CTD |
PMID:31669396 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[Flavones co-treated with Lipopolysaccharides] results in increased phosphorylation of RELA protein |
CTD |
PMID:31669396 |
|
NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469
|
|
|
G |
CASP3 |
caspase 3 |
decreases expression |
EXP |
3-hydroxyflavone results in decreased expression of CASP3 protein |
CTD |
PMID:21126572 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases expression |
EXP |
3-hydroxyflavone results in increased expression of MAPK1 protein |
CTD |
PMID:21126572 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases expression |
EXP |
3-hydroxyflavone results in increased expression of MAPK3 protein |
CTD |
PMID:21126572 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
|
G |
GJA1 |
gap junction protein alpha 1 |
affects expression |
EXP |
Flutamide affects the expression of GJA1 mRNA |
CTD |
PMID:20961722 |
|
NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein |
CTD |
PMID:29129240 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
CBS |
cystathionine beta-synthase |
multiple interactions increases activity |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CBS protein Folic Acid deficiency results in increased activity of CBS protein |
CTD |
PMID:16792574 |
|
NCBI chr13:206,205,942...206,231,363
Ensembl chr13:206,205,946...206,230,248
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in decreased expression of CSF2 mRNA |
CTD |
PMID:14662146 |
|
NCBI chr 2:134,354,724...134,357,155
Ensembl chr 2:134,354,724...134,357,155
|
|
G |
CTH |
cystathionine gamma-lyase |
multiple interactions |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CTH protein |
CTD |
PMID:16792574 |
|
NCBI chr 6:142,454,922...142,486,352
Ensembl chr 6:142,454,914...142,486,367
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
|
|
G |
DNMT3A |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GCLC protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GCLC mRNA |
CTD |
PMID:16792574 |
|
NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA |
CTD |
PMID:29129240 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions increases activity increases expression |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSR protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSR mRNA Folic Acid deficiency results in increased activity of GSR protein Folic Acid deficiency results in increased expression of GSR mRNA |
CTD |
PMID:16792574 |
|
NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984
|
|
G |
GSS |
glutathione synthetase |
multiple interactions |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSS protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSS mRNA |
CTD |
PMID:16792574 |
|
NCBI chr17:38,316,199...38,342,253
Ensembl chr17:38,312,720...38,342,298
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSTA1 mRNA Folic Acid deficiency results in increased expression of GSTA1 mRNA |
CTD |
PMID:16792574 |
|
NCBI chr 7:46,538,743...46,550,781
Ensembl chr 7:46,538,032...46,548,670
|
|
G |
GYS1 |
glycogen synthase 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter |
CTD |
PMID:29065941 |
|
NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
EXP |
[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter |
CTD |
PMID:29065941 |
|
NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
|
|
G |
MTHFR |
methylenetetrahydrofolate reductase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA |
CTD |
PMID:28445388 |
|
NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in decreased expression of PTGS1 |
CTD |
PMID:14662146 |
|
NCBI chr 1:262,456,106...262,482,159
Ensembl chr 1:262,456,155...262,483,035
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Folic Acid co-treated with Glycine] results in increased expression of PTGS2 |
CTD |
PMID:14662146 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
SI |
sucrase-isomaltase |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA |
CTD |
PMID:28445388 |
|
NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA |
CTD |
PMID:28445388 |
|
NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases activity multiple interactions |
EXP |
Folic Acid deficiency results in decreased activity of SOD1 protein [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA; [Ethanol co-treated with Folic Acid deficiency] results in decreased activity of SOD1 protein |
CTD |
PMID:16792574 PMID:29129240 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions increases activity |
EXP |
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of SOD2 protein Folic Acid deficiency results in increased activity of SOD2 protein; Folic Acid results in increased activity of SOD2 protein |
CTD |
PMID:16792574 PMID:22889112 |
|
NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
|
|
|
G |
FES |
FES proto-oncogene, tyrosine kinase |
multiple interactions decreases phosphorylation |
EXP |
Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein]; Gefitinib inhibits the reaction [VEGFA protein results in increased phosphorylation of FES protein] Gefitinib results in decreased phosphorylation of FES protein |
CTD |
PMID:19885553 |
|
NCBI chr 7:53,472,947...53,485,084
Ensembl chr 7:53,472,947...53,485,082
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein] |
CTD |
PMID:19885553 |
|
NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Gefitinib inhibits the reaction [VEGFA protein results in increased phosphorylation of FES protein] |
CTD |
PMID:19885553 |
|
NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366
|
|
|
G |
ESR1 |
estrogen receptor 1 |
decreases expression |
EXP |
Genistein results in decreased expression of ESR1 protein |
CTD |
PMID:22443950 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Genistein inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Genistein inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Penicillins]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Genistein inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein] |
CTD |
PMID:18840580 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions |
EXP |
GSK2656157 inhibits the reaction [deoxynivalenol results in increased expression of ATF4 protein] |
CTD |
PMID:37442268 |
|
NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
GSK2656157 inhibits the reaction [deoxynivalenol results in increased expression of DDIT3 protein] |
CTD |
PMID:37442268 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
EIF2A |
eukaryotic translation initiation factor 2A |
multiple interactions |
EXP |
GSK2656157 inhibits the reaction [deoxynivalenol results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:37442268 |
|
NCBI chr13:90,761,453...90,804,274
Ensembl chr13:90,761,465...90,804,274
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
GSK2656157 inhibits the reaction [deoxynivalenol results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:37442268 |
|
NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [Cocaine results in increased expression of EDN1 protein] |
CTD |
PMID:9714087 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases metabolic processing multiple interactions |
EXP |
HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide; chromium mesoporphyrin inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]; tin protoporphyrin IX inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide] |
CTD |
PMID:16751286 |
|
|
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
Hexachlorobenzene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Hexachlorobenzene results in decreased expression of and results in decreased secretion of ADIPOQ protein |
CTD |
PMID:28284726 |
|
NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646
|
|
G |
ADIPOR1 |
adiponectin receptor 1 |
decreases expression |
EXP |
Hexachlorobenzene results in decreased expression of ADIPOR1 protein |
CTD |
PMID:28284726 |
|
NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686
|
|
G |
ADIPOR2 |
adiponectin receptor 2 |
decreases expression |
EXP |
Hexachlorobenzene results in decreased expression of ADIPOR2 protein |
CTD |
PMID:28284726 |
|
NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
increases expression |
EXP |
Hexachlorobenzene results in increased expression of CYP11A1 protein |
CTD |
PMID:21296658 |
|
NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
decreases expression |
EXP |
Hexachlorobenzene results in decreased expression of CYP17A1 protein |
CTD |
PMID:21296658 |
|
NCBI chr14:113,805,616...113,820,445
Ensembl chr14:113,805,611...113,812,041
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
decreases expression |
EXP |
Hexachlorobenzene results in decreased expression of CYP19A1 protein |
CTD |
PMID:21296658 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
HSD17B1 |
hydroxysteroid 17-beta dehydrogenase 1 |
decreases expression |
EXP |
Hexachlorobenzene results in decreased expression of HSD17B1 protein |
CTD |
PMID:21296658 |
|
NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548
|
|
|
G |
HRH2 |
histamine receptor H2 |
multiple interactions |
EXP |
[Histamine affects the activity of HRH2 protein] which affects the secretion of Chlorides |
CTD |
PMID:12665126 |
|
NCBI chr 2:81,883,670...81,932,464
Ensembl chr 2:81,883,673...81,932,275
|
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21798251 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21798251 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
|
G |
CAT |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein] |
CTD |
PMID:21984542 |
|
NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
|
|
G |
XDH |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Hydrogen Peroxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Superoxides; CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein]; tempol inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; tempol results in decreased activity of [Hypoxanthine co-treated with XDH protein] |
CTD |
PMID:21984542 |
|
NCBI chr 3:107,987,060...108,052,043
Ensembl chr 3:107,987,126...108,053,169
|
|
|
G |
AGT |
angiotensinogen |
affects activity |
| |